Interstitial lung diseases and, in particular, idiopathic

Size: px
Start display at page:

Download "Interstitial lung diseases and, in particular, idiopathic"

Transcription

1 Assessment of Health-Related Quality of Life in Patients With Interstitial Lung Disease* Jacqueline A. Chang, MD; J. Randall Curtis, MD, MPH; Donald L. Patrick, PhD, MSPH; and Ganesh Raghu, MD, FCCP Study objectives: Health-related quality of life associated with interstitial lung disease has received little attention in clinical studies because there have been no validated methods for directly measuring it. We have assessed the validity of several generic and respiratory-specific quality-of-life instruments in patients with interstitial lung disease. Design: Cross-sectional study. Setting: Outpatient pulmonary clinic at a university referral center. Patients: Fifty patients with interstitial disease such as idiopathic pulmonary fibrosis, sarcoidosis, hypersensitivity pneumonitis, and asbestosis. Interventions: Patients were administered four quality-of-life questionnaires, the Medical Outcomes Study Short Form 36 (SF-36), the Quality of Well-being scale (QWB), the Chronic Respiratory Questionnaire (CRQ), and the St. George s Respiratory Questionnaire (SGRQ). Patients concomitantly underwent pulmonary function testing and performed a 6-min walk. Measurements and results: Validation of these instruments was based on testing an a priori hypothesis that worse quality-of-life scores should correlate with more severe physiologic impairment demonstrated by pulmonary function tests, exercise tolerance on the 6-min walk, and dyspnea scores. Our patients, on average, had a moderate degree of physiologic impairment and demonstrated moderately decreased quality-of-life scores. Scores from all four quality-of-life questionnaires correlated significantly with 6-min walk distance and dyspnea score. Scores from the SF-36, QWB, and SGRQ showed significant correlation with FVC, FEV 1, and diffusing capacity as well. The SF-36 and SGRQ consistently showed the strongest correlation with physical impairment. Conclusions: Our findings indicate that preexisting quality-of-life instruments can be applied to patients with interstitial lung disease and suggest that the SF-36 and the SGRQ, in particular, are sensitive tools for assessing quality of life in these patients. Future intervention studies of patients with interstitial lung disease should consider using these measures. (CHEST 1999; 116: ) Key words: health status indicators; lung diseases; interstitial; pulmonary fibrosis; quality of life Abbreviations: CRQ Chronic Respiratory Questionnaire; Dlco diffusing capacity of the lung for carbon monoxide; MCS Mental Component Score; 6MW 6-min walk; 6MWD 6-min-walk distance; PCS Physical Component Score; QWB Quality of Well-Being Scale; SF-36 Medical Outcomes Short Form 36; SGRQ St. Gearoge s Respiratory Questionnaire; TLC total lung capacity *From the Division of Pulmonary and Critical Care Medicine, Department of Medicine (Drs. Chang, Curtis, and Raghu), and the Department of Health Services (Drs. Curtis and Patrick), University of Washington, Seattle, WA. Supported in part by the Respiratory Research Training grant, No. 5 T32 HL Additional project support was provided by the Firland Sheltered Workshop Foundation, a nonprofit agency with a mission of support for projects relating to care of individuals with tuberculosis and other chronic respiratory problems. Manuscript received February 22, 1999; revision accepted June 8, Correspondence to: Ganesh Raghu, MD, FCCP, Division of Pulmonary and Critical Care Medicine, University of Washington, Box , Seattle, WA 98195; graghu@ washington.edu Interstitial lung diseases and, in particular, idiopathic pulmonary fibrosis are chronic progressive diseases with significant morbidity and mortality. The median survival for idiopathic pulmonary fibrosis is 3 to 5 years with half of the deaths resulting from progressive respiratory failure. 1,2 As the disease progresses, patients invariably become severely limited in their activities and dependent on supplemental oxygen. Current medical regimens have not been shown to improve survival but, nevertheless, are routinely prescribed with the hope of slowing progression of disease. 3 5 Currently available medica- CHEST / 116 / 5/ NOVEMBER,

2 tions, particularly corticosteroids and immunosuppressives, are all associated with significant side effects and morbidity. Colchicine has been used without significant side effects but does not appear to be significantly more effective than corticosteroids. 5 Toxicity of therapy is one important reason why quality of life should be considered a separate therapeutic end point in addition to stability of disease by pulmonary function or radiographic severity. However, clinicians and researchers have primarily followed physiologic and radiographic end points because there are no validated methods for directly measuring quality of life in this patient population. Standardized and validated methods for assessing the health-related quality of life in interstitial lung disease are needed to better understand the effect of these diseases and to evaluate standard and new therapies. Since the early 1980s, several standardized generic quality-of-life questionnaires have been developed to measure health-related quality of life for a variety of diseases Subsequently, respiratory-specific quality-of-life questionnaires were created to specifically address the problems faced by patients with chronic pulmonary disease. 11 Although many of these questionnaires were designed originally for patients with COPD, they have been applied to other patient populations as well In this study we have evaluated whether these generic and respiratory-specific questionnaires could be used to assess quality of life in patients with interstitial lung diseases. The validity of quality-of-life instruments is established primarily by demonstrating their content and construct validity. In applying well-established instruments to new patient populations, however, it is perhaps most important to demonstrate construct validity. 15 The premise of construct validation is that quality-of-life instruments should provide unique information not provided by objective measurements but, nevertheless, should correlate to some degree with severity of disease measured by these physiologic variables. Our hypothesis a priori was that worse quality-of-life scores should moderately correlate with more severe physiologic impairment demonstrated by pulmonary function tests, 6-min-walk distance (6MWD), and dyspnea. Most of the instruments also have subscale scores, which are designed to evaluate specific aspects of quality of life. Subscale scores focusing on physical or functional impairment would be expected to correlate better with pulmonary function than subscale scores focusing on mental or emotional health. We have used construct validation as the basis of our evaluation of four health-related quality-of-life instruments for patients with interstitial lung disease. Patients Materials and Methods All patients with documented interstitial lung disease referred to or followed by the University of Washington Chest Clinic from September 1997 through July 1998 were identified by screening clinic appointment books and were asked to participate if they met entry criteria. Interstitial lung disease was defined by the clinical presentation of otherwise unexplained dyspnea in conjunction with (1) linear or reticulonodular interstitial infiltrates on chest radiograph or CT scan, and (2) restrictive pulmonary function or consistent histopathologic findings. A total lung capacity (TLC) 80% of predicted was used as the criterion for defining restrictive physiology. Patients were excluded if they had any of the following: interstitial lung disease secondary to collagen vascular disease, nonparenchymal restrictive lung disease such as neuromuscular weakness or skeletal abnormality, obstructive lung disease such as COPD or asthma, or active coronary artery disease or other comorbid illness precluding performance of the 6-min walk (6MW) test. This case definition included patients with idiopathic pulmonary fibrosis, chronic sarcoidosis, chronic hypersensitivity pneumonitis, and asbestosis. Patients with idiopathic pulmonary fibrosis had histopathology consistent with either usual interstitial pneumonitis or nonspecific interstitial pneumonitis or met the clinical criteria of slowly progressive dyspnea of unknown cause and bibasilar infiltrates. Chronic sarcoidosis was diagnosed by the presence of noncaseating granulomas in all patients except one, who had typical radiographic features and a high CD4/CD8 ratio within a lymphocyte-predominant lavage fluid. The diagnosis of chronic hypersensitivity pneumonitis was based on the clinical history of exposure to a known offending antigen and confirmatory histopathology. Asbestosis was diagnosed primarily by clinical criteria including a history of heavy occupational exposure, although some patients had ferruginous bodies on tissue biopsy as well. Seventy-seven eligible patients were identified, and 50 patients participated after providing written informed consent. The most common reason patients did not participate was the traveling distance to the study center (n 10). Other reasons for nonenrollment were time conflicts with work (n 5), inability to contact patients (n 4), and patient disinterest (n 5). Only three patients were too sick to participate or died before study enrollment. All study procedures were approved by the University of Washington Human Subjects Committee. Study Design The study was a cross-sectional comparison of scores from two generic and two respiratory-specific health-related quality-of-life instruments with physiologic data from pulmonary function tests and a 6MW test. Patients were asked to complete the four quality-of-life questionnaires in a randomized order based on a random numbers table. After completing each questionnaire, patients were asked to rate how well the content of the questionnaire addressed quality-of-life issues relevant to their disease on a 1 (worst) to 10 (best) scale. Immediately after answering the questionnaires, the patients performed a modified 6MW test. The standard 6MW has been shown to be a reliable, valid, and safe method of assessing functional status in both patients with COPD and congestive heart failure. 16,17 Our protocol for the 6MW was adjusted slightly for patient comfort and safety. Patients were allowed to stop and restart during the 6 min if necessary. Although 6MW tests are sometimes performed multiple times to account for a learning effect, only one test was performed 1176 Clinical Investigations

3 because of many patients severe exercise limitation. 18 In addition, patients were deliberately allowed to use supplemental oxygen at the same inspired concentration normally used with their daily activities. After completing the walk, patients rated the amount of dyspnea experienced during the test on a standard Borg scale. 19 Patients underwent pulmonary function testing including spirometry, plethysmography, and diffusing capacity within 2 months of answering the questionnaires. Two months was believed to be the maximal length of time of stability in pulmonary function for this population. Two-thirds of the patients had pulmonary function tests within 1 week of the questionnaires, and half of the patients had tests on the same day. All tests were performed in accordance with published standards FVC, FEV 1, TLC, and diffusing capacity of the lung for carbon monoxide (Dlco) were expressed as percent of normal based on age, sex, race, and height-adjusted population standards. 23 Dlco was adjusted for hemoglobin concentration. Health-Related Quality-of-Life Questionnaires Medical Outcomes Short Form 36: The Medical Outcomes Short Form 36 (SF-36) is a generic health-related quality-of-life instrument, which has been used to assess quality of life in a variety of chronic medical conditions including COPD and asthma. 24,25 Its validity, reproducibility, and responsiveness to changes over time have been well demonstrated. 8 It assesses eight dimensions of quality of life: physical function, role limitation caused by physical impairment, bodily pain, general health, vitality, social function, role limitation caused by emotional impairment, and mental health. Each dimension is scored separately on a 0 to 100 scale, in which higher scores correspond to better quality of life. The SF-36 also incorporates the subscale scores into two summary measures, the Physical Component Score (PCS) and the Mental Component Score (MCS), which provide a measure of the overall effect of physical and mental impairment on quality of life. These summary scores are standardized to responses from the general population, whose mean score is 50. Quality of Well-Being Scale: The Quality of Well-Being Scale (QWB) is a general health outcome and health utility measure, which has been validated in patients with a variety of medical conditions including COPD. 9,10,26 Its questions focus on symptoms and medical problems, mobility, physical activity, and impact of illness on activities of daily living, and it summarizes these into one score ranging from 0 (death) to 1.0 (perfect health). Chronic Respiratory Questionnaire: The Chronic Respiratory Questionnaire (CRQ) is a respiratory-specific quality-oflife instrument originally developed for patients with COPD, which has been validated in patients with asthma as well. 13,27,28 It assesses four aspects of quality of life: dyspnea, fatigue, emotional function, and mastery. The questionnaire has a unique format, which allows patients to rate the severity of dyspnea associated with individually identified activities. Scores for each of the four domains and the summary score have a range from 0 to 100, in which higher scores signify better health-related quality of life. St. George s Respiratory Questionnaire: The St. George s Respiratory Questionnaire (SGRQ) is a respiratory-specific instrument developed for patients with COPD. Its validity, reproducibility, and response to change over time have been demonstrated in patients with COPD, asthma, and bronchiectasis. 12,14,29 It has three components: symptoms, which measures respiratory symptoms; activities, which measures impairment of mobility or physical activity; and impacts, which measures the psychosocial impact of disease. Scores for these components and the summary score are on a 100-point scale, which is opposite in direction to the other three instruments. Higher scores correspond to worse health-related quality of life. Statistical Analysis Correlation between quality-of-life scores and pulmonary function tests, 6MWD, and dyspnea score were evaluated using Pearson s coefficient. Quality-of-life scores were plotted against physiologic measures on scatter plots to ensure a linear relationship between the two (data not shown). Linear regression methods were then used to determine whether physiologic measures remained independent predictors of quality-of-life scores after considering patient demographics and comorbid illness. Two-sample Student s t tests were used to determine whether quality-of-life scores differed between patients who were dependent on supplemental oxygen and patients who were not. Analysis of variance was used to assess whether quality-of-life scores differed between patients by diagnosis. The criteria for statistical significance was set at p The Friedman test, a nonparametric test similar to analysis of variance for repeated measures, was used to test for significant differences in patient ratings between the four questionnaires. 30 Results Clinical Characteristics We administered quality-of-life questionnaires to 50 patients with interstitial lung disease. The clinical characteristics of this group are described in Table 1. The median age of the patients was 60.5 years with a range from 29 to 81 years. The older age and male predominance of the study population reflect the epidemiologic features of its largest group, idiopathic pulmonary fibrosis. The majority of patients were currently taking or had been previously taking steroids and other immunosuppressives. Seventy-six percent of the patients were currently or previously taking high-dose steroids ( 40 mg/d), whereas 34% of the patients were currently maintained on steroids at lower doses ( 40 mg/d). A quarter of the patients were dependent on supplemental oxygen. Seventy-eight percent of the patients had at least one stable comorbid illness. Comorbid conditions included non insulin-dependent diabetes mellitus without end-organ damage, stable coronary disease, or arthralgia attributed to degenerative joint disease. Physiologic Characteristics On average, the study group had moderately severe restrictive lung disease indicated by their FVC and FEV 1 (Table 2). There was a larger decrement in the mean Dlco. However, the values for the FVC, FEV 1, and Dlco varied widely from values indicative of a severe restrictive defect to values within normal limits (defined as 80% of predicted). CHEST / 116 / 5/ NOVEMBER,

4 Table 1 Baseline Clinical Characteristics of 50 Patients With Interstitial Lung Disease* Table 2 Physiologic and Functional Severity of Disease for 50 Patients With Interstitial Lung Disease Variable Variable Median No. of Patients Percentage of Patients Sex Male Female Age 50 yr yr Diagnosis IPF Sarcoidosis Asbestosis, misc Biopsy-proven diagnosis Overall IPF Sarcoidosis 9 90 Asbestosis, misc Comorbidities Non-rheumatoid joint disease Steroid use Currently on high dose ( 40 mg/d) 3 6 Currently on low dose ( 40 mg/d) Not currently on steroids Other immunosuppressives Azathioprine, currently Azathioprine, previously Cyclophosphamide, currently 1 2 Cyclophosphamide, previously 6 12 Supplemental oxygen use *IPF idiopathic pulmonary fibrosis; misc. miscellaneous. Interquartile Range Minimum Maximum FVC, % predicted FEV 1, % predicted TLC, % predicted Dlco, % predicted MWD, feet 1,421 1,130 1, ,235 Borg dyspnea score Similarly, the study group had on average a moderate decrease in exertional capacity illustrated by the mean 6MWD of 1,360 feet (Table 2). The 6MWDs from other studies provide some comparison. The average 6MWD for a group of healthy men, whose average age was 60 years old, was 1,728 feet (576 m), and the average 6MWD for patients awaiting hip replacement was approximately 600 feet (300 m). 31,32 The 6MWD for our population, like the pulmonary function tests, encompassed a wide range from severe limitation (315 feet) to normal (2,235 feet). Most of the patients reported light to moderate dyspnea during the 6MW: dyspnea ratings on the Borg scale had a bimodal distribution with peaks at 0.5 and 4 (Table 2). Even though patients were allowed to perform the test using oxygen if they normally used it, 38% of the group still exhibited desaturations to 88%. Health-Related Quality of Life The summary scores from each of the four quality-of-life instruments are shown in Table 3. The summary scores of the SF-36, the PCS and the MCS, were standardized to scores from the general population, which conform to a normal distribution with a mean of 50. The mean PCS for our patients signified on average a moderately severe degree of impairment compared with the general population. The larger decrease in the PCS compared with the MCS suggested a more significant impairment in the physical aspects of quality of life than the emotional aspects of healthrelated quality of life. However, there was a wide range among individuals. The extremely low minimal values observed indicated an extremely poor health-related quality of life on both a physical and an emotional level for some individuals. The mean QWB score was similarly decreased. However, individual responses fell within a narrower range. Both the total scores from the SGRQ and the CRQ indicated a moderate decrease in quality of life Table 3 Health-Related Quality-of-Life Scores for 50 Patients With Interstitial Lung Disease Instrument Median Interquartile Range Minimum Maximum SF-36 Physical function Bodily pain Role physical General health Vitality Social function Role emotional Mental health PCS MCS QWB SGRQ Symptom score Activity score Impact score Total score CRQ Dyspnea Fatigue Emotional function Mastery Total score Clinical Investigations

5 because their medians were considerably below the midpoint of the scales. Individual responses on both questionnaires, but in particular the SGRQ, nearly covered the entire range of possible scores. Analysis of variance revealed no significant differences in the quality-of-life scores between patients with idiopathic pulmonary fibrosis and patients with other interstitial lung diseases (p values ranged from 0.6 to 1.0 for the four instruments.) Furthermore, the pattern of association between quality-of-life scores and physiologic variables for the subgroup of patients with idiopathic pulmonary fibrosis was similar to that seen for the entire cohort (data not shown). Therefore the results for the two groups were combined in the subsequent analysis evaluating the correlation between quality-of-life scores and physiologic measurements. Validation of Health-Related Quality-of-Life Measures With Physiologic Variables Scores from all four of the quality-of-life instruments showed statistically significant correlation with pulmonary function test results (Table 4). The PCS of the SF-36 and the QWB score were correlated with FVC, FEV 1, and Dlco. However, their correlation with TLC was not statistically significant. The CRQ score was only correlated with Dlco. Of the five quality-of-life scores, the SGRQ total score was most strongly correlated with pulmonary function. Its correlation with the FVC, FEV 1, and Dlco was stronger than its correlation with TLC. The MCS of the SF-36 did not show a statistically significant correlation with any of the pulmonary function tests. Scores from all four of the quality-of-life questionnaires were correlated with 6MWD and dyspnea rating. The PCS was more strongly correlated with 6MWD and dyspnea than the QWB score. Likewise the SGRQ score showed a stronger correlation than the CRQ score. The MCS did not show statistically significant correlation with either variable. Long-term supplemental oxygen use was statistically associated with lower PCS, QWB, SGRQ, and CRQ scores (t 2.774, 2.131, 4.718, and 3.355, respectively; p 0.05). However, resting oxygen saturation, exertional oxygen saturation, and the presence of exercise-induced desaturation were not associated with quality-of-life scores from any of the instruments. An additional method of validating the quality-of-life instruments was to assess the correlation between individual subscale scores and the physiologic data. Of the eight individual subscale scores of the SF-36, only physical function was statistically correlated with FVC% (r 0.38, p 0.01). Although the subscale scores of the SGRQ do not clearly delineate physical aspects of quality of life from emotional aspects, the activity score was expected to correlate with physiologic variables better than would the symptom score. The correlation coefficients for these subscale scores were consistent with our hypothesis: the FVC% was more strongly correlated with activity score (r 0.39, p 0.01) than the symptom score (r 0.31, p 0.05). Similarly, for the CRQ, the dyspnea score was significant correlated with the FVC% (r 0.32, p 0.05), whereas the fatigue score and the emotional score were not. Demographic and physiologic variables were entered into multiple linear regression models to ascertain whether pulmonary function, walk distance, and dyspnea were independent predictors of qualityof-life scores. Even after considering age, oxygen use, and comorbidity, pulmonary function tests, 6MWD, and dyspnea remained significant independent predictors of the SF-36 PCS score and the SGRQ total score (data not shown). There were no significant differences in the patients ratings of the questionnaires in terms of the extent to which their content addressed relevant quality-of-life issues ( , p 0.81). The median ratings of the questionnaires (1 and 10 as the worst and best ratings, respectively) were as follows: 9.0 (SF-36), 8.5 (QWB), 8.5 (CRQ), and 8.5 (SGRQ). Table 4 Pearson Correlation Coefficients (r) Between Quality-of-Life Scores and Pulmonary Function Tests and 6MWD for 50 Patients With Interstitial Lung Disease FVC, % predicted FEV 1,% predicted TLC, % predicted Dlco, % predicted 6MWD, ft Dyspnea Score SF-36-PCS 0.31* 0.30* * SF-36-MCS QWB 0.29* 0.28* * SGRQ total score CRQ total score * 0.53 *p p CHEST / 116 / 5/ NOVEMBER,

6 Discussion Health-related quality of life in interstitial lung disease is a vital concern to both patients and their physicians. Patients experience decreased quality of life because of symptoms and treatment side effects as well as the progressive nature of the respiratory impairment and functional limitation caused by the disease. Physicians should be particularly concerned about quality-of-life issues with these diseases because medications currently available are of marginal effectiveness, particularly in the case of idiopathic pulmonary fibrosis, and are associated with significant adverse effects. Standardized quality-of-life measures are essential for characterizing and assessing the quality of life in this patient population. Our data support the validity of using preexisting health-related quality-of-life questionnaires to assess the health-related quality of life of patients with interstitial lung disease. Our evaluation of the SF-36, QWB, SGRQ, and CRQ was based on construct validation. Scores from all four of the quality-of-life instruments correlated with severity of physical impairment reflected by pulmonary function, 6MWD, and dyspnea rating. In addition to assessing whether these instruments were valid in this population, we were interested in determining whether some instruments were better than others. We based our judgment on the strength of the association between the quality-of-life scores and the physiologic measurements as well as the patient ratings of the questionnaire content. There were no significant differences in the patient ratings of the questionnaires. In comparing the two generic questionnaires, the PCS was consistently more strongly correlated with pulmonary function, 6MWD, and dyspnea rating than the QWB score. Likewise, between the two respiratory-specific instruments, the SGRQ total score was more strongly associated with all physiologic measurements than the CRQ score. Our findings suggested that the SF-36 and the SGRQ may be more-sensitive instruments for discriminating differences in quality of life between individuals with varying degrees of physical impairment caused by interstitial lung disease. Observations from the study suggested possible reasons why the QWB and the CRQ may be lesssensitive quality-of-life instruments. Although our study population represented the full spectrum of disease severity, their QWB scores fell within a relatively narrow range. Because of the lesser variability in QWB scores, this generic questionnaire may be less successful in distinguishing between patients with interstitial lung disease. The few questions that addressed respiratory symptoms were answered in a similar manner by most patients, whereas much of the variability in the scores resulted from nonrespiratory symptoms and problems. The scores on the CRQ had more variability than the QWB but less variability than the SF-36 and the SGRQ. Although the CRQ is a respiratory-specific quality-of-life instrument, its individualized format may have accounted for why its scores were less consistently correlated with pulmonary function than the SGRQ. With the CRQ, patients rated the severity of their dyspnea based on symptoms during their own daily activities. In our study we observed that patients with the most severe disease frequently scaled down their activities to minimize dyspnea and therefore did not consistently report more dyspnea on the questionnaire. This explanation could have accounted for the attenuated difference in scores between patients with mild and severe physiologic impairment. The CRQ may be better suited for longitudinal follow-up of patients than comparisons between individuals. The correlation between the quality-of-life scores and pulmonary function tests and 6MW tests in this population with interstitial lung disease were similar to those described in patients with COPD and asthma. Several investigators found significant correlation of similar magnitude between the SGRQ total score and subscale scores and FEV 1 and FVC in patients with COPD (r 0.28 to 0.51). 12,33 Similarly, they found a statistically significant association between quality-of-life scores and 6MWD (r 0.26 to 0.59). 12 The SF-36 has been tested less extensively in COPD, but the correlation found by Jones and colleagues 34 is similar to our findings. Other investigators have identified strong correlation between CRQ scores and the 6MW, but the correlation between CRQ scores and pulmonary function tests have been less consistent in other studies as well. 13,27,35 Kaplan and colleagues 10 also found a significant correlation between the QWB score and FVC and FEV 1 in patients with COPD. In our study, we found a significant correlation between health-related quality of life and the need for supplemental oxygen but no association between quality of life and oxygenation at rest or during exercise. The association between health-related quality-of-life scores and oxygenation reported by other investigators has been inconsistent. Although Jones and colleagues 12 found no significant correlation between scores from the SGRQ and resting oxygen saturation in patients with COPD, Okubadejo et al 36 did find a statistically significant association between scores on this questionnaire and Pao 2. Our results are not necessarily contradictory to the findings of Okubadejo and colleagues. 36 In their study, none of the patients were using long-term oxygen therapy although it was initiated in some 1180 Clinical Investigations

7 based on the low arterial oxygen noted. Impaired oxygenation may not necessarily be associated with poorer quality of life provided that patients can use long-term supplemental oxygen. Additionally, the amount of oxygen individual patients use may vary with their different daily activities and may not be the same as the average amount of oxygen use reported and consequently used during our 6MW tests. One potential limitation of our study is that the patient population was a referral population, which may differ from patients with interstitial lung disease in the community. Our patients had, on average, moderately severe restrictive lung disease by physiologic criteria supporting a possible referral bias. However, the severity of illness varied from severe physiologic defects to within normal limits, and therefore our sample provides a reasonable representation of the complete spectrum of disease. Another limitation of our study is the possibility that we did not accurately assess the patients maximal exercise tolerance because the 6MW was only performed once. The potential inaccuracy of the 6MWD is unlikely to jeopardize the validity of our results, because the association between the 6MWD and the quality-of-life scores was highly statistically significant (p 0.01). However, inaccuracy in measuring the 6MWD may have affected our estimate of the magnitude of the correlation. In summary, we have demonstrated that a general measure, the SF-36, and a respiratory-specific measure, the SGRQ, are sensitive instruments for evaluating health-related quality of life in patients with interstitial lung disease. These findings are an important first step to the application of standardized quality-of-life measurements in clinical research. Our cross sectional study has shown that the SF-36 and the SGRQ can be used to examine the healthrelated quality of life of this patient population and how it varies based on severity of disease. Future studies are needed to address the ability of these instruments to assess change over time. The outcomes of these studies, in combination with our results, will allow selection of specific quality-of-life instruments as end points in clinical trials to evaluate the efficacy of new therapies. ACKNOWLEDGMENT: The authors would like to thank the persons with interstitial lung disease who participated in this study. References 1 Tukiainen P, Taskinen E, Holsti P, et al. Prognosis of cryptogenic fibrosing alveolitis. Thorax 1983; 38: Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis. Chest 1998; 113: Johnson MA, Kwan S, Snell NJC, et al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebocontrolled clinical trial. Am Rev Respir Dis 1991; 144: Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: McHorney CA, Ware JE, Rogers W, et al. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Med Care 1992; 30: MS253 MS265 7 Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36). Med Care 1992; 30: Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. JAMA 1989; 262: Ries AL, Kaplan RM, Limberg TM, et al. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122: Kaplan RM, Atkins CJ, Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J Chronic Dis 1984; 37: Curtis JR, Martin DP, Martin TR. Patient-assessed health outcomes in chronic lung disease. Am J Respir Crit Care Med 1997; 156: Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis 1992; 145: Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: Wilson CB, Jones PW, O Leary CJ, et al. Validation of the St. George s Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156: Guyatt GH, Feeny DH, Patrick DL. Measuring healthrelated quality of life. Ann Intern Med 1993; 118: Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-min walk test in patients with left ventricular dysfunction. JAMA 1993; 270: Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6 min walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132: Guyatt GA, Pugsley SO, Sullivan MJ. Effect of encouragement on walking test performance. Thorax 1984; 39: Burdon JG, Juniper EF, Killian KJ, et al. The perception of breathlessness in asthma. Am Rev Respir Dis 1982; 126: Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J 1993; 6(suppl): Standardization of spirometry: 1987 update; statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136: Single breath carbon monoxide diffusing capacity (transfer factor) recommendations for a standard technique: statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136: Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: CHEST / 116 / 5/ NOVEMBER,

8 24 Mahler DA, Faryniarz K, Tomlinson D, et al. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease. Chest 1992; 102: Mahler DA, Mackowiak JI. Evaluation of the Short Form 36-Item questionnaire to measure health -related quality of life in patients with COPD. Chest 1995; 107: Anderson JP, Kaplan RM, Berry CC, et al. Interday reliability of function assessment for a health status measure: the quality of well-being scale. Med Care 1989; 27: Guyatt GH, Townsend M, Keller J, et al. Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir Med 1989; 83: Wijkstra PJ, Ten Vergert EM, Van Altena R, et al. Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax 1994; 49: Jones PW. Measurement of health in asthma and chronic obstructive airways disease. Pharm Med 1992; 6: Altman DG. In: Practical statistics for medical research. London: Chapman and Hall, 1991; Enright PL, Sherrill DL. Reference equations for the sixminute walk in healthy adults. Am J Respir Crit Care Med 1998; 158: Johanson NA, Charlson ME, Szatrowski TP, et al. A selfadministered hip-rating questionnaire for the assessment of outcome after total hip replacement. J Bone Joint Surg 1992; 74: Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127: Jones PW, Bosh T. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: Wijkstra PJ, Ten Vergert EM, van der Mark TW, et al. Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. Thorax 1994; 49: Okubadejo AA, Jones PW, Wedzicha JA. Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxemia. Thorax 1996; 51: Clinical Investigations

Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR)

Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR) 954 Department of Respiratory Medicine, University Hospitals of Leicester, Glenfield Hospital, Leicester LE3 9QP, UK J E A Williams S J Singh L Sewell M D L Morgan Department of Clinical Epidemiology and

More information

DIAGNOSTIC NOTE TEMPLATE

DIAGNOSTIC NOTE TEMPLATE DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the

More information

C hronic obstructive pulmonary disease (COPD) is one of

C hronic obstructive pulmonary disease (COPD) is one of 589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See

More information

Development and validity testing of an IPF-specific version of the St George s Respiratory Questionnaire

Development and validity testing of an IPF-specific version of the St George s Respiratory Questionnaire < Additional data are published online only. To view these files please visit the journal online (http://thorax.bmj.com). 1 School of Nursing, Faculty of Health and Social Care, University of Salford,

More information

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma

A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires

More information

Pulmonary rehabilitation (PR) is an important

Pulmonary rehabilitation (PR) is an important Power of Outcome Measurements to Detect Clinically Significant Changes in Pulmonary Rehabilitation of Patients With COPD* Juan Pablo de Torres, MD; Victor Pinto-Plata, MD; Edward Ingenito, MD; Peter Bagley,

More information

Validity and Reliability of CAT and Dyspnea-12 in Bronchiectasis and Tuberculous Destroyed Lung

Validity and Reliability of CAT and Dyspnea-12 in Bronchiectasis and Tuberculous Destroyed Lung http://dx.doi.org/10.4046/trd.2012.72.6.467 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2012;72:467-474 CopyrightC2012. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights

More information

Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life?

Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life? Is there any evidence that multi disciplinary pulmonary rehabilitation impacts on quality of life? Summary of the evidence located: According to the NICE guideline on Chronic Obstructive Pulmonary Disease

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published

More information

Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire*

Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire* Original Research COPD Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire* Makiko Meguro, Mphil; Elizabeth A. Barley, PhD, CPsychol; Sally Spencer,

More information

A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD

A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD RESPIRATORY MEDICINE (2001) 95, 71 77 doi:10.1053/rmed.2000.0976, available online at http://www.idealibrary.com on A comparison of three disease-specific and two generic health-status measures to evaluate

More information

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD?

Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? AUTHOR COPY ORIGINAL RESEARCH Does the multidimensional grading system (BODE) correspond to differences in health status of patients with COPD? Kian-Chung Ong 1 Suat-Jin Lu 1 Cindy Seok-Chin Soh 2 1 Department

More information

Chapter 5: Patient-reported Health Instruments used for people with Chronic Obstructive Pulmonary Disease (COPD)

Chapter 5: Patient-reported Health Instruments used for people with Chronic Obstructive Pulmonary Disease (COPD) Chapter 5: Patient-reported Health Instruments used for people with Chronic Obstructive Pulmonary Disease (COPD) Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality

More information

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease Thorax 1999;54:581 586 581 Academic Department of Respiratory Medicine, St Bartholomew s and Royal London School of Medicine and Dentistry, London Chest Hospital, London, UK EAPaul R Garrod R Garnham J

More information

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation

More information

Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects

Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects Use of GOLD and ATS Criteria Connie Paladenech, RRT, RCP, FAARC Benefits and Limitations of Pulmonary Function Testing Benefits

More information

Differential diagnosis

Differential diagnosis Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential

More information

Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis

Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis original article Randomized Trial of in Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* ABSTRACT Background has been suggested as a beneficial treatment for idiopathic

More information

PSYCHOMETRIC ASSESSMENT OF THE CHINESE LANGUAGE VERSION OF THE ST. GEORGE S RESPIRATORY QUESTIONNAIRE IN TAIWANESE PATIENTS WITH BRONCHIAL ASTHMA

PSYCHOMETRIC ASSESSMENT OF THE CHINESE LANGUAGE VERSION OF THE ST. GEORGE S RESPIRATORY QUESTIONNAIRE IN TAIWANESE PATIENTS WITH BRONCHIAL ASTHMA St. George's Respiratory Questionnaire PSYCHOMETRIC ASSESSMENT OF THE CHINESE LANGUAGE VERSION OF THE ST. GEORGE S RESPIRATORY QUESTIONNAIRE IN TAIWANESE PATIENTS WITH BRONCHIAL ASTHMA Kwua-Yun Wang, Chi-Hue

More information

Patient Assessment Quality of Life

Patient Assessment Quality of Life Patient Assessment Quality of Life STEP 1 Learning objectives This module will provide you with an understanding of the importance of assessing Quality of Life (QoL) in patients and the role that quality

More information

Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients

Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients Brazilian Journal of Medical and Biological Research (2007) 40: 179-187 Quality of life in idiopathic pulmonary fibrosis ISSN 0100-879X 179 Comparison of two questionnaires which measure the health-related

More information

Interpreting thresholds for a clinically significant change in health status in asthma and COPD

Interpreting thresholds for a clinically significant change in health status in asthma and COPD Eur Respir J 2002; 19: 398 404 DOI: 10.1183/09031936.02.00063702 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Interpreting thresholds for

More information

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life

SGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective

More information

호흡재활치료 울산의대서울아산병원 호흡기내과 이상도

호흡재활치료 울산의대서울아산병원 호흡기내과 이상도 호흡재활치료 울산의대서울아산병원 호흡기내과 이상도 Systemic (Extrapulmonary) effects in COPD Skeletal muscle dysfunction Osteoporosis Weight loss Sexual dysfunction Cardiovascular diseases (Gross et al., Curr Opin Pulm Med 2001;7:84)

More information

Reliability and validity of a Swedish version of the St George's Respiratory Questionnaire

Reliability and validity of a Swedish version of the St George's Respiratory Questionnaire Eur Respir J 1998; 11: 61 66 DOI: 1.1183/931936.98.11161 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1998 European Respiratory Journal ISSN 93-1936 Reliability and validity of a Swedish

More information

Exercise Rehabilitation and Chronic Obstructive Pulmonary Disease Stage

Exercise Rehabilitation and Chronic Obstructive Pulmonary Disease Stage Exercise Rehabilitation and Chronic Obstructive Pulmonary Disease Stage MICHAEL J. BERRY, W. JACK REJESKI, NORMAN E. ADAIR, and DANIEL ZACCARO Department of Health and Exercise Science, Department of Public

More information

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD)

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD) ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the

More information

Division of Pulmonary, Critical Care, and Sleep Medicine, Jacksonville, FL. Department of Internal Medicine, Wichita, KS

Division of Pulmonary, Critical Care, and Sleep Medicine, Jacksonville, FL. Department of Internal Medicine, Wichita, KS in Patients with Respiratory Disease Furqan Shoaib Siddiqi, M.D. 1, Said Chaaban, M.D. 2, Erin Petersen, M.S.N., A.P.R.N. 3, K James Kallail, Ph.D. 2, Mary Hope, B.H.S., A.R.T., R.R.T., C.P.F.T. 3, Daniel

More information

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene

Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.

More information

The assessment of health status among patients with COPD

The assessment of health status among patients with COPD Eur Respir J 2003; 21: Suppl. 41, 36s 45s DOI: 10.1183/09031936.03.00078102 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0904-1850 The assessment

More information

Douglas W. Mapel MD, MPH, Melissa Roberts PhD

Douglas W. Mapel MD, MPH, Melissa Roberts PhD Original Article Spirometry, the St. George s Respiratory Questionnaire, and other clinical measures as predictors of medical costs and COPD exacerbation events in a prospective cohort Douglas W. Mapel

More information

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.

More information

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies: Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the

More information

Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index

Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index Chronic Respiratory Disease 2009; 6: 75 80 http://crd.sagepub.com ORIGINAL PAPER Health-related quality of life is associated with COPD severity: a comparison between the GOLD staging and the BODE index

More information

To Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure

To Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure To Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure Pramila S Kudtarkar*, Mariya P Jiandani*, Ashish Nabar** Abstract Purpose

More information

Chapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension

Chapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension Chapter 7 Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension P. Trip B. Girerd H.J. Bogaard F.S. de Man A. Boonstra G. Garcia M. Humbert D. Montani A. Vonk Noordegraaf Eur Respir

More information

Understanding the Basics of Spirometry It s not just about yelling blow

Understanding the Basics of Spirometry It s not just about yelling blow Understanding the Basics of Spirometry It s not just about yelling blow Carl D. Mottram, RRT RPFT FAARC Technical Director - Pulmonary Function Labs and Rehabilitation Associate Professor of Medicine -

More information

What do pulmonary function tests tell you?

What do pulmonary function tests tell you? Pulmonary Function Testing Michael Wert, MD Assistant Professor Clinical Department of Internal Medicine Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical

More information

A.A. Okubadejo*, E.A. Paul*, P.W. Jones**, J.A. Wedzicha

A.A. Okubadejo*, E.A. Paul*, P.W. Jones**, J.A. Wedzicha Eur Respir J, 1996, 9, 2335 2339 DOI: 10.1183/09031936.96.09112335 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1996 European Respiratory Journal ISSN 0903-1936 Does long-term oxygen

More information

OFEV MEDIA BACKGROUNDER

OFEV MEDIA BACKGROUNDER OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Interpreting pulmonary function tests: Recognize the pattern, and the diagnosis will follow

Interpreting pulmonary function tests: Recognize the pattern, and the diagnosis will follow REVIEW FEYROUZ AL-ASHKAR, MD Department of General Internal Medicine, The Cleveland Clinic REENA MEHRA, MD Department of Pulmonary and Critical Care Medicine, University Hospitals, Cleveland PETER J. MAZZONE,

More information

Survival in Patients With Cryptogenic Fibrosing Alveolitis*

Survival in Patients With Cryptogenic Fibrosing Alveolitis* Survival in Patients With Cryptogenic Fibrosing Alveolitis* A Population-Based Cohort Study Richard Hubbard, DM; Ian johnston, MD; and john Britton, MD Study objectives: To determine the median survival

More information

Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease

Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease Thorax 1997;52:67 71 67 Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease L M Osman, D J Godden, JARFriend, J S Legge, J G Douglas Abstract not differ from

More information

Pulmonary Function Testing The Basics of Interpretation

Pulmonary Function Testing The Basics of Interpretation Pulmonary Function Testing The Basics of Interpretation Jennifer Hale, M.D. Valley Baptist Family Practice Residency Objectives Identify the components of PFTs Describe the indications Develop a stepwise

More information

ORIGINAL INVESTIGATION

ORIGINAL INVESTIGATION ORIGINAL INVESTIGATION Baseline Oxygen Saturation Predicts Exercise Desaturation Below Prescription Threshold in Patients With Chronic Obstructive Pulmonary Disease Mark T. Knower, MD; Donnie P. Dunagan,

More information

Pulmonary Function Testing

Pulmonary Function Testing In the Clinic Pulmonary Function Testing Hawa Edriss MD, Gilbert Berdine MD The term PFT encompasses three different measures of lung function: spirometry, lung volumes, and diffusion capacity. In this

More information

Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital

Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital Prapaporn Pornsuriyasak, M.D. Pulmonary and Critical Care Medicine Ramathibodi Hospital Only 20-30% of patients with lung cancer are potential candidates for lung resection Poor lung function alone ruled

More information

PFT Interpretation and Reference Values

PFT Interpretation and Reference Values PFT Interpretation and Reference Values September 21, 2018 Eric Wong Objectives Understand the components of PFT Interpretation of PFT Clinical Patterns How to choose Reference Values 3 Components Spirometry

More information

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary

More information

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study 36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E

More information

Minimal important difference of the transition dyspnoea index in a multinational clinical trial

Minimal important difference of the transition dyspnoea index in a multinational clinical trial Eur Respir J 2003; 21: 267 272 DOI: 10.1183/09031936.03.00068503a Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0903-1936 Minimal important difference

More information

ONLINE DATA SUPPLEMENT - ASTHMA INTERVENTION PROGRAM PREVENTS READMISSIONS IN HIGH HEALTHCARE UTILIZERS

ONLINE DATA SUPPLEMENT - ASTHMA INTERVENTION PROGRAM PREVENTS READMISSIONS IN HIGH HEALTHCARE UTILIZERS R2 (REVISED MANUSCRIPT BLUE 200208-877OC) ONLINE DATA SUPPLEMENT - ASTHMA INTERVENTION PROGRAM PREVENTS READMISSIONS IN HIGH HEALTHCARE UTILIZERS Mario Castro, M.D., M.P.H. Nina A. Zimmermann R.N. Sue

More information

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to

More information

This is a cross-sectional analysis of the National Health and Nutrition Examination

This is a cross-sectional analysis of the National Health and Nutrition Examination SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is

More information

Comparison of respiratory health-related quality of life in patients with intractable breathlessness due to advanced cancer or advanced COPD

Comparison of respiratory health-related quality of life in patients with intractable breathlessness due to advanced cancer or advanced COPD Comparison of respiratory health-related quality of life in patients with intractable breathlessness due to advanced cancer or advanced COPD Shagayegh Javadzadeh, BA (Hons) Cantab University of School

More information

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical

More information

Patient Reported Outcomes

Patient Reported Outcomes Patient Reported Outcomes INTRODUCTION TO CLINICAL RESEARCH A TWO-WEEK INTENSIVE COURSE, 2010 Milo Puhan, MD, PhD, Associate Professor Key messages Patient-reported outcomes (PRO) is a broad group of outcomes

More information

Recent evidence-based guidelines recommend

Recent evidence-based guidelines recommend Original Article Pulmonary rehabilitation improves only some domains of health-related quality of life measured by the Short Form-36 questionnaire Chok Limsuwat, Ryan McClellan, Hoda Mojazi Amiri, Kenneth

More information

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment

More information

Diffuse Interstitial Lung Diseases: Is There Really Anything New?

Diffuse Interstitial Lung Diseases: Is There Really Anything New? : Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There

More information

PREDICTION EQUATIONS FOR LUNG FUNCTION IN HEALTHY, LIFE TIME NEVER-SMOKING MALAYSIAN POPULATION

PREDICTION EQUATIONS FOR LUNG FUNCTION IN HEALTHY, LIFE TIME NEVER-SMOKING MALAYSIAN POPULATION Prediction Equations for Lung Function in Healthy, Non-smoking Malaysian Population PREDICTION EQUATIONS FOR LUNG FUNCTION IN HEALTHY, LIFE TIME NEVER-SMOKING MALAYSIAN POPULATION Justin Gnanou, Brinnell

More information

International consensus statement on idiopathic pulmonary fibrosis

International consensus statement on idiopathic pulmonary fibrosis Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic

More information

Patient reported outcomes in respiratory diseases; How to assess clinical success in COPD

Patient reported outcomes in respiratory diseases; How to assess clinical success in COPD Patient reported outcomes in respiratory diseases; How to assess clinical success in COPD Thys van der Molen, University of Groningen, Department of General Practice, The Netherlands Mr Valette Smoking

More information

Regulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1).

Regulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.05 Subject: Ofev Page: 1 of 5 Last Review Date: March 17, 2017 Ofev Description Ofev (nintedanib)

More information

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test? Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard

More information

A Validation Study for the Korean Version of Chronic Obstructive Pulmonary Disease Assessment Test (CAT)

A Validation Study for the Korean Version of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) http://dx.doi.org/10.4046/trd.2013.74.6.256 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;74:256-263 CopyrightC2013. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights

More information

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis JULIE A. BJORAKER, JAY H. RYU, MARK K. EDWIN, JEFFREY L. MYERS, HENRY D. TAZELAAR, DARRELL R. SCHROEDER, and KENNETH

More information

TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than

TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients

More information

Manuscript type: Research letter

Manuscript type: Research letter TITLE PAGE Chronic breathlessness associated with poorer physical and mental health-related quality of life (SF-12) across all adult age groups. Authors Currow DC, 1,2,3 Dal Grande E, 4 Ferreira D, 1 Johnson

More information

Ontario s Referral and Listing Criteria for Adult Lung Transplantation

Ontario s Referral and Listing Criteria for Adult Lung Transplantation Ontario s Referral and Listing Criteria for Adult Lung Transplantation Version 3.0 Trillium Gift of Life Network Adult Lung Transplantation Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The patient

More information

Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept.

Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Plan Chronic Respiratory Disease Definition Factors Contributing

More information

Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust

Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust Interstitial Lung Disease (ILD) Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust The views expressed in this presentation are those of the speaker and are not necessarily those

More information

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

Original Contributions

Original Contributions Original Contributions Comparison of a New Desktop Spirometer (Spirospec) with a Laboratory Spirometer in a Respiratory Out-Patient Clinic François Swart, Macé M Schuurmans MD, Johannes C Heydenreich,

More information

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +

More information

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives

More information

Idiopathic pulmonary fibrosis (IPF) is the. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is the. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis Eur Respir J 2010; 36: 1067 1072 DOI: 10.1183/09031936.00152609 CopyrightßERS 2010 A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis O. Nishiyama*,", H. Taniguchi*,

More information

COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases

COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose

More information

Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study

Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study Eur Respir J 2002; 20: 306 312 DOI: 10.1183/09031936.02.00301002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Ambulatory oxygen improves

More information

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,

More information

Until approximately 40 yrs ago, clinical. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis REVIEW: IPF

Until approximately 40 yrs ago, clinical. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis REVIEW: IPF Eur Respir Rev 2012; 21: 124, 147 151 DOI: 10.1183/09059180.00000912 CopyrightßERS 2012 REVIEW: IPF Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis Luca Richeldi ABSTRACT:

More information

Health-related quality of life in COPD: why both disease-specific and generic measures should be used

Health-related quality of life in COPD: why both disease-specific and generic measures should be used Eur Respir J 2001; 18: 69 76 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Health-related quality of life in COPD: why both disease-specific

More information

PULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests

PULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests PULMONARY FUNCTION TESTING Wyka Chapter 13 Various AARC Clinical Practice Guidelines Purposes of Pulmonary Tests Is lung disease present? If so, is it reversible? If so, what type of lung disease is present?

More information

Differential diagnosis

Differential diagnosis Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between

More information

The 6-min walk distance: change over time and value as a predictor of survival in severe COPD

The 6-min walk distance: change over time and value as a predictor of survival in severe COPD Eur Respir J 2004; 23: 28 33 DOI: 10.1183/09031936.03.00034603 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2004 European Respiratory Journal ISSN 0903-1936 The 6-min walk distance: change

More information

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,

More information

Relationship Between FEV1& PEF in Patients with Obstructive Airway Diseases

Relationship Between FEV1& PEF in Patients with Obstructive Airway Diseases OBSTRUCTIVE THE IRAQI POSTGRADUATE AIRWAY MEDICAL DISEASES JOURNAL Relationship Between FEV1& PEF in Patients with Obstructive Airway Diseases Muhammed.W.AL.Obaidy *, Kassim Mhamed Sultan*,Basil Fawzi

More information

Author s Accepted Manuscript

Author s Accepted Manuscript Author s Accepted Manuscript Low levels of physical activity predict worse survival to lung transplantation and poor early postoperative outcomesphysical activity level in lung transplantation James R.

More information

COPD Bronchiectasis Overlap Syndrome.

COPD Bronchiectasis Overlap Syndrome. COPD Bronchiectasis Overlap Syndrome. John R Hurst 1, J Stuart Elborn 2, and Anthony De Soyza 3 on Behalf of the BRONCH-UK Consortium (D Bilton, J Bradley, JS Brown, J Duckers, F Copeland, A Floto, J Foweraker,

More information

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and

More information

Quality of Life and Related Factors in Patients with Chronic Obstructive Pulmonary Disease

Quality of Life and Related Factors in Patients with Chronic Obstructive Pulmonary Disease 51 Quality of Life and Related Factors in Patients with COPD ORIGINAL RESEARCH ARTICLE Tanaffos (2006) 5(3), 51-56 2006 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran Quality

More information

Patient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens

Patient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough

More information

PULMONARY REHABILITATION Current Evidence and Recommendations

PULMONARY REHABILITATION Current Evidence and Recommendations PULMONARY REHABILITATION Current Evidence and Recommendations Overview Introduction to Pulmonary Rehabilitation Pathophysiolgy of Exercise Limitation Exercise training Current evidence for COPD Current

More information

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Outpatient Pulmonary Rehabilitation

Outpatient Pulmonary Rehabilitation Outpatient Pulmonary Rehabilitation Policy Number: 8.03.05 Last Review: 7/2017 Origination: 7/1995 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for

More information

Quality of life in patients with chronic respiratory disease: the Spanish version of the Chronic Respiratory Questionnaire (CRQ)

Quality of life in patients with chronic respiratory disease: the Spanish version of the Chronic Respiratory Questionnaire (CRQ) Eur Respir J 1998; 11: 55 60 DOI: 10.1183/09031936.98.11010055 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1998 European Respiratory Journal ISSN 0903-1936 Quality of life in patients

More information

Physiotherapy Program, Faculty of Allied Health Sciences Jalan Raja Muda Abdul Aziz, Kuala Lumpur 2

Physiotherapy Program, Faculty of Allied Health Sciences Jalan Raja Muda Abdul Aziz, Kuala Lumpur 2 : 21-26 A Measure of Health-related Quality of Life (HRQoL) of COPD Patients Following Pulmonary Rehabilitation Program with Two Health Index Questionnaire (SF-36 and SGRQ) 1 R Ayiesah*, 2 S Riza & 1 ZY

More information